JP2022501389A5 - - Google Patents

Info

Publication number
JP2022501389A5
JP2022501389A5 JP2021516763A JP2021516763A JP2022501389A5 JP 2022501389 A5 JP2022501389 A5 JP 2022501389A5 JP 2021516763 A JP2021516763 A JP 2021516763A JP 2021516763 A JP2021516763 A JP 2021516763A JP 2022501389 A5 JP2022501389 A5 JP 2022501389A5
Authority
JP
Japan
Prior art keywords
sbcma
antibody
seq
monoclonal antibody
indicated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021516763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501389A (ja
JP7596260B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053433 external-priority patent/WO2020069303A1/en
Publication of JP2022501389A publication Critical patent/JP2022501389A/ja
Publication of JP2022501389A5 publication Critical patent/JP2022501389A5/ja
Priority to JP2024100215A priority Critical patent/JP2024147571A/ja
Application granted granted Critical
Publication of JP7596260B2 publication Critical patent/JP7596260B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021516763A 2018-09-28 2019-09-27 可溶性ｂｃｍａに対する抗体 Active JP7596260B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024100215A JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862738997P 2018-09-28 2018-09-28
US62/738,997 2018-09-28
PCT/US2019/053433 WO2020069303A1 (en) 2018-09-28 2019-09-27 Antibodies against soluble bcma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024100215A Division JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Publications (3)

Publication Number Publication Date
JP2022501389A JP2022501389A (ja) 2022-01-06
JP2022501389A5 true JP2022501389A5 (enExample) 2022-10-04
JP7596260B2 JP7596260B2 (ja) 2024-12-09

Family

ID=68296657

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021516763A Active JP7596260B2 (ja) 2018-09-28 2019-09-27 可溶性ｂｃｍａに対する抗体
JP2024100215A Withdrawn JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024100215A Withdrawn JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Country Status (11)

Country Link
US (1) US11505614B2 (enExample)
EP (1) EP3856781A1 (enExample)
JP (2) JP7596260B2 (enExample)
KR (1) KR102994831B1 (enExample)
CN (1) CN112703204B (enExample)
AR (1) AR116548A1 (enExample)
BR (1) BR112021005669A2 (enExample)
MA (1) MA53732A (enExample)
TW (1) TW202028239A (enExample)
UY (1) UY38393A (enExample)
WO (1) WO2020069303A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE068401T2 (hu) * 2019-11-11 2024-12-28 Amgen Res Munich Gmbh A BCMA elleni hatóanyagok adagolási rendje
EP4611774A2 (en) * 2022-11-04 2025-09-10 MiNK Therapeutics, Inc. B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof
WO2024168192A1 (en) * 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
CN119529089B (zh) * 2023-08-28 2025-11-18 菲鹏生物股份有限公司 一种抗生长刺激表达基因2蛋白的抗体及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1985A (en) 1841-02-18 Charles m
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
CA2169298A1 (en) 1993-09-10 1995-03-16 Martin Chalfie Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
ATE290205T1 (de) 1996-12-12 2005-03-15 Prolume Ltd Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
ES2207278T3 (es) 1998-07-28 2004-05-16 Micromet Ag Heterominicuerpos.
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
EP2714737A1 (en) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
WO2014151910A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Heterodimeric bispecific antibodies
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
WO2015048272A1 (en) 2013-09-25 2015-04-02 Amgen Inc. V-c-fc-v-c antibody
EP3029068A1 (en) * 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
JP6901493B2 (ja) * 2015-11-13 2021-07-14 アメリカ合衆国 抗ｂｃｍａポリペプチド及びタンパク質
DK3402515T3 (da) * 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
UA126657C2 (uk) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>

Similar Documents

Publication Publication Date Title
AU2022203322B2 (en) Improved methods of assessing UCH-L1 status in patient samples
JP2023002583A (ja) Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
AU2018272054B2 (en) Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
AU2018378971A1 (en) Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1)
AU2018378084A1 (en) Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
WO2018175942A1 (en) Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
EP3237004A1 (en) Predicting outcome of treatment with an anti- 4 7 integrin antibody
WO2015013388A2 (en) Anti-galectin-1 monoclonal antibodies and fragments thereof
JP2022031643A (ja) Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０
WO2013188494A1 (en) Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
US12055552B2 (en) Method for diagnosis based on circulating extracellular vesicles
JP6580570B2 (ja) 抗体安定性を向上させるための方法
JP2022501389A (ja) 可溶性ｂｃｍａに対する抗体
JP2020526745A (ja) 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
EP3602069A1 (en) Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
EP4396587A1 (en) Methods and systems of diagnosing brain injury
CN118715440A (zh) 诊断脑损伤的方法和系统
Fichtner et al. Self-antigen driven affinity maturation is required for pathogenic monovalent IgG4 autoantibody development
WO2025037271A1 (en) Plasma assay for detecting cns-derived tau peptides
HK40123156A (en) Improved methods of assessing uch-l1 status in patient samples
WO2024226971A1 (en) Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
WO2022245920A9 (en) Methods of evaluating brain injury in a pediatric subject
EA045805B1 (ru) Анализы для выявления нейродегенеративных заболеваний
HK1237281B (en) Soluble human st-2 antibodies and assays